改进肝脏影像报告和数据系统M类标准以提高MRI对≤3.0 cm肝细胞癌诊断性能的新策略
回顾性分析384例肝细胞癌风险患者中463个病理证实的≤3.0 cm肝脏病灶,评估LI-RADS v2018的LR-M特征。新LR-M标准(2个及以上显著特征)使LR-5诊断肝细胞癌的敏感度从65%提高至69%(p=0.002),特异度相似(90% vs 92%,p=0.28)。
要点
- 新LR-M标准为满足以下4个特征中2个及以上:环形动脉期高强化、延迟期中心强化、靶样弥散受限、靶样移行期/肝胆期表现。
- 新标准使LR-5诊断≤3.0 cm肝细胞癌的敏感度从65%升至69%,特异度与原始标准相似(90% vs 92%)。
- 环形动脉期高强化、延迟期中心强化、靶样弥散受限、靶样移行期/肝胆期表现与非肝细胞癌恶性肿瘤独立显著相关(校正OR≥6.2)。
核心结论
- 新LR-M标准(2个及以上显著特征)可提高LR-5诊断≤3.0 cm肝细胞癌的敏感度,而不降低特异度。
研究设计与样本
- 回顾性分析384例肝细胞癌风险患者的463个病理证实≤3.0 cm肝脏病灶(375个肝细胞癌、32个其他恶性肿瘤、56个良性病变),均行钆塞酸二钠增强MRI;两名放射科医师按LI-RADS v2018评估主要、辅助及LR-M特征。
关键影像表现/征象
- 10个LR-M特征中,环形动脉期高强化、延迟期中心强化、靶样弥散受限、靶样移行期/肝胆期表现与非肝细胞癌恶性肿瘤独立显著相关(校正OR≥6.2;p≤0.02)。
- 新LR-M标准定义为上述4个显著特征中满足2个及以上。
诊断标准与关键数值
- 新LR-M标准(2个及以上显著特征)时,LR-5诊断肝细胞癌的敏感度为69%(95%CI 64-73%),原始LR-M标准为65%(95%CI 61-70%),p=0.002。
- 新LR-M标准时LR-5诊断肝细胞癌的特异度为90%(95%CI 82-95%),原始LR-M标准为92%(95%CI 83-96%),p=0.28。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: We aimed to determine a new strategy for Liver Imaging Reporting and Data System category M (LR-M) criteria to improve the diagnosis of HCC ≤ 3.0 cm on magnetic resonance imaging (MRI).
METHODS: A total of 463 pathologically confirmed hepatic observations ≤ 3.0 cm (375 HCCs, 32 other malignancies, 56 benignities) in 384 patients at risk of HCC who underwent gadoxetate-enhanced MRI were retrospectively analyzed. Two radiologists evaluated the presence of major, ancillary, and LR-M features according to LI-RADS v2018. Of the ten LR-M features, those significantly associated with non-HCC malignancy were identified using multivariable logistic regression analysis, and new LR-M criteria for improving the diagnosis of HCC were investigated. Generalized estimating equations were used to compare sensitivity and specificity of LR-5 for diagnosing HCC using the new LR-M criteria with values calculated using the original LR-M criteria. p < 0.05 was considered to indicate a significant difference.
RESULTS: Of ten LR-M features, rim arterial-phase hyperenhancement, delayed central enhancement, targetoid restriction, and targetoid transitional-phase/hepatobiliary-phase appearance were independently significantly associated with non-HCC malignancy (adjusted odds ratio ≥ 6.2; p ≤ 0.02). Using the new LR-M criteria (two or more of these significant features), the sensitivity of LR-5 for diagnosing HCC was higher than that with the original LR-M criteria (69% [95% confidence interval 64-73%] vs. 65% [61-70%], p = 0.002), whereas the specificity was similar (90% [82-95%] vs. 92% [83-96%], p = 0.28).
CONCLUSION: The new LR-M criteria (two or more significant features) can improve the sensitivity of LR-5 for diagnosing HCC ≤ 3.0 cm, without compromising specificity.
引用
- Jang, Choi, Byun, et al. New strategy for Liver Imaging Reporting and Data System category M to improve diagnostic performance of MRI for hepatocellular carcinoma ≤ 3.0 cm. Abdom Radiol (NY). 2022. PMID: 35523888. doi:10.1007/s00261-022-03538-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。